RPL17 and non-small cell lung carcinoma: Immune-checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) or its ligand programmed death ligand 1 (PD-L1) are recommended by the National Comprehensive Cancer Network (NCCN) (6) and the European Society of Medical Oncology (ESMO) (7) for locally advanced and metastatic NSCLC without targetable genetic alterations.